Armis Expands Technology Partner Ecosystem to Help Global Organizations Fortify Cyber Defenses
12.11.2025 14:00:00 CET | Business Wire | Press release
Strategic integrations unify cyber capabilities, enhancing joint customers’ existing technology stacks
Armis, the cyber exposure management & security company, today announced 11 new global technology integration partners. These integrations enhance joint customers’ existing technology stacks, enabling them to streamline security operations and reduce their cyber risk exposure.
“The era of fragmented security is over – organizations demand best-in-class solutions that work seamlessly together to solve today's most complex cybersecurity challenges,” said Nadir Izrael, CTO and Co-Founder at Armis. “By partnering with other industry leaders, we are not just integrating tools; we are delivering a unified security ecosystem that reduces complexity and empowers joint customers to optimize their technology investments. This supports businesses in staying ahead of threats and protecting their most critical assets with confidence.”
New Armis global technology integration partners include BlastWave, Cato Networks, Checkmarx, CyCognito, Elastic, Onyxia Cyber, Profitap, TeamDynamix, Tines, Sygnia, and Virsec. These new integrations further strengthen Armis' partner ecosystem, expanding on the growth announced earlier this year, and bring immediate value to joint customers:
- “The joint solution is a game-changer for our customers. By leveraging insights from Armis Centrix™ and the Cato SASE Platform, we enhance visibility, classification, and policy definition – empowering security teams to identify and then protect Internet of Things (IoT) and operational technology (OT) devices in factories and offices across the globe from one console.” –Ofir Agasi, Chief Product Officer of Cato Networks
- “Together, Armis and CyCognito are bridging the gap between external and internal exposures and identifying attackers’ path of least resistance. By integrating CyCognito’s external attack surface management platform with Armis Centrix™, we are delivering the industry’s first truly comprehensive internal and external exposure management solution. This enables joint customers to map critical attack paths, prioritize based on real-world exploitability and accelerate remediation.” –Rob Gurzeev, CEO of CyCognito
- “IoT and unmanaged assets remain some of the most challenging blind spots for security teams today. Armis’ deep contextual insights, combined with Elastic's open and extensible platform and its AI-driven SOC operations, enable analysts to bring in any data for faster detection, smarter investigations, and quicker responses, all in one place.” –Mike Nichols, GM of Elastic Security
- “In complex cyber crises, speed and context are everything. When Sygnia begins incident response efforts with an organization that has already deployed the Armis Centrix™ platform, our responders can tap its comprehensive, real-time visibility across managed and unmanaged assets. This enhanced context accelerates investigations and recovery planning, helping organizations return to business faster and stronger.” –Guy Segal, CEO of Sygnia
Armis continues to experience great demand driven by its award-winning Cyber Exposure Management Platform, Armis Centrix™. Most recently, the company was named a Leader in The Forrester Wave™: IoT Security Solutions, Q3 2025 and The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. Armis was also recognized earlier this year as a Leader in the Gartner® Magic Quadrant™ for CPS Protection Platforms.
Additional partner organizations shared the following benefits of working with Armis:
- “At Profitap, we’re dedicated to delivering uncompromised network visibility and performance at scale. Our integration with Armis Centrix™ takes that mission further, turning lossless network data into real-time, actionable intelligence. By combining Profitap’s reliable traffic access with Armis’ deep asset intelligence and automated threat response, organizations gain complete visibility across every network layer, eliminating blind spots and empowering faster, more confident security decisions.” –Geoffrey Kempenich, CEO of Profitap
- “Security teams need both speed and comprehensive insights to stay ahead of evolving threats. By combining Armis’ real-time asset intelligence with Tines intelligent workflows, teams can uncover unseen risks, orchestrate responses, and strengthen their security posture across the entire environment.” –John Schimelpfenig, Director, Technology Partnerships of Tines
Learn more about Armis’ global technology integration partners here.
About Armis
Armis, the cyber exposure management & security company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112892711/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom